Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy

Phase 2 Completed 42 enrolled Eli Lilly and Company

NaSingle-groupOpen-labelTreatment

Summary

A study to determine how long ramucirumab (IMC-1121B) will stop cancer from growing in participants with liver cancer that cannot be treated with surgery.

Timeline

Start: 2008-02
Primary completion: 2011-05
Completion: 2011-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ramucirumab	Monoclonal antibody	8 mg/kg	—

Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy

Summary

Timeline

Drugs

Indications